In Reply We thank Drs D’Ascanio, Ricci, and Piazza for their interest in the article “Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial.”1 The contribution of the article was a retrospective subgroup analysis of a randomized trial of primary radiation with and without cetuximab for patients with locoregionally advanced head and neck cancers. Patients with advanced laryngeal and hypopharyngeal tumors often require laryngectomy if they are to undergo surgery. We examined patients with advanced laryngeal and hypopharyngeal tumors from our overall trial2,3 of patients with locoregionally advanced head and neck cancer.
Bonner JA, Chin S, Spencer S. Cetuximab and Radiotherapy in Laryngeal Preservanion—Reply. JAMA Otolaryngol Head Neck Surg. 2017;143(5):526. doi:https://doi.org/10.1001/jamaoto.2016.3809
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: